Ûnreinheden fan Amino-soer brûkt foar synthesize proteïne
Produkt detail
| NO | Produkten | CAS NO | Yndikator foar kaai kwaliteit | |||
| Suverens | Maks. ûnminfruchtigens | Totaal Solvent-residu | Focht | |||
| 1 | Fmoc-β-ala-ala-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 2 | Fmoc-d-ala-d-ala-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 3 | Fmoc-β-ala-d-ala-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 4 | FMOC-ARG (PBF) -Arg (PBF) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 5 | Fmoc-β-ala-arg (PBF) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 6 | FMOC-D-ARG (PBF) -D-ARG (PBF) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 7 | FMOC-β-ALA-D-ARG (PBF) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 8 | Fmoc-homoarg (pbf) -homoarg (pbf) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 9 | Fmoc-β-ala-homoarg (pbf) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 10 | FMOC-ASN (TRT) -Asn (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 11 | Fmoc-β-ala-asn (trt) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 12 | FMOC-ASP (OTBU) -ASp (OTBU) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 13 | FMOC-β-ALA-ASP (OTBU) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 14 | FMOC-CYS (trt) -cys (trt) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 15 | FMOC-β-ALA-CYS (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 16 | Fmoc-cys (ACM) -cys (ACM) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 17 | FMOC-β-ALA-CYS (ACM) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 18 | Fmoc-gln (trt) -gln (trt) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 19 | FMOC-β-ALA-GLN (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 20 | FMOC-GLU (OTBU) -GLU (OTBU) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 21 | FMOC-β-ALA-GLU (OTBU) -OH.H2O | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 22 | Fmoc-β-ala-gly-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 23 | FMOC-SY (TRT) -HIS (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 24 | FMOC-β-Ala-SY (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 25 | Fmoc-ile-ile-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 26 | Fmoc-β-ala-ile-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 27 | FMOC-leu-leu-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 28 | Fmoc-β-ala-leu-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 29 | FMOC-D-Leu-D-Leu-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 30 | Fmoc-β-ala-d-leu-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 31 | FMOC-LYS (BOC) -lys (BOC) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 32 | Fmoc-β-ala-lys (Boc) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 33 | Fmoc-lys (alloc) -lys (alloc) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 34 | Fmoc-β-ala-lys (alloc) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 35 | Fmoc-met-met-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 36 | Fmoc-β-ala-met-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 37 | FMOC-orn (Boc) -orn (Boc) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 38 | Fmoc-β-ala-orn (Boc) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 39 | FMOC-PHE-PHE-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 40 | Fmoc-β-ala-phe-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 41 | FMOC-D-PHE-D-PHE-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 42 | Fmoc-β-ala-d-phe-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 43 | Fmoc-pro-pro-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 44 | Fmoc-β-ala-pro-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 45 | FMOC-SER (TBU) -Ser (TBU) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 46 | Fmoc-β-ala-ser (TBU) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 47 | Fmoc-ser (trt) -ser (trt) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 48 | Fmoc-β-ala-ser (trt) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 49 | Fmoc-thr (tbu) -thr (tbu) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 50 | Fmoc-β-ala-thr (tbu) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 51 | FMOC-TRP (BOC) -TRP (BOC) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 52 | FMOC-β-ALA-TRP (BOC) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 54 | FMOC-β-ALA-D-TRP (BOC) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 55 | FMOC-Tyr (TBU) -tyr (TBU) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 56 | Fmoc-β-ala-Tyr (TBU) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 57 | FMOC-D-Tyr (ET) -D-Tyr (ET) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 58 | Fmoc-β-ala-d-Tyr (ET) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 59 | Fmoc-tyr (me) -tyr (my) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 60 | Fmoc-β-ala-tyr (my) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 61 | FMOC-VAL-VAL-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 62 | Fmoc-β-ala-val-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 64 | Fmoc-β-ala-d-cit-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 65 | Fmoc-β-ala-dab-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 66 | Fmoc- (3- (2-naphthyl) -d-ala) 2-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 67 | Fmoc-β-ala-3- (2-naphthyl) -d-ala-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 68 | Fmoc- (3- (3-pyridinyl) -d-ala) 2-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 69 | Fmoc-β-ala-3- (3-pyridinyl) -D-ala-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 70 | Fmoc- (4 chloro-d-phe) 2-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 71 | Fmoc-β-ala-4-chloro-d-phe-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 72 | FMOC- (D-4AFH (TBUCBM)) 2-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 73 | Fmoc-β-ala-d-4afge (TBucbm) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 74 | FMOC-APH (L-Hor) -ap -ap (L-Hor) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 75 | Fmoc-β-ala-aph (L-hor) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 76 | FMOC-LYS (IPR, BOC) -lys (IPR, BOC) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 77 | FMOC-β-Ala-Lys (IPR, BOC) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 78 | Fmoc-β-ala-aeea-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 79 | Fmoc-aib-aib-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 80 | Fmoc-β-ala-aib-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 81 | FMOC-ARG-OH | 91000-69-0 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 82 | H-arg (PBF) -oh | 200115-86-2 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 83 | FMOC-D-ARG-OH | 130752-32-8 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 84 | HD-ARG (PBF) -Oh | 200116-81-0 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 86 | H-Homoarg (PBF) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 87 | Fmoc-d-homoarg-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 88 | HD-Homoarg (PBF) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 89 | FMOC-ASN-OH | 71989-16-7 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 91 | FMOC-ASP-OH | 119062-05-4 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 92 | H-ASP (OTBU) -oh | 3057-74-7 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 93 | FMOC-CYS-OH | 135248-89-4 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 94 | H-CYS (TRT) -OH | 2799/7/7 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 95 | H-CYS (ACM) -Oh.HCL | 28798-28-9 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 96 | FMOC-GLN-OH | 71989-20-3 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 97 | H-GLN (TRT) -OH | 102747-84-2 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 98 | FMOC-GLU-OH | 121343-82-6 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 99 | H-GLU (OTBU) -OH.H2O | 2419-56-9 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 100 | Fmoc-syn-oh | 116611-64-4 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 101 | H-SY (TRT) -OH | 35146-32-8 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 102 | Boc-syn-oh | 17791-52-5 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 103 | FMOC-LYS-OH | 105047-45-8 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 104 | H-LYS (BOC) -oh | 2418-95-3 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 105 | H-LYS (ALLOC) -OH | 6298/3/9 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 106 | FMOC-ORN-OH.HCL | 201046-57-3 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 107 | H-Orn (Boc) -oh | 13650-49-2 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 108 | FMOC-SER-OH | 73724-45-5 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 109 | H-SER (TBU) -oh | 18822-58-7 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 110 | H-SER (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 112 | H-thr (tbu) -oh | 4378-13-6 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 113 | FMOC-TRP-OH | 35737-15-6 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 114 | H-TRP (BOC) -oh | 146645-63-8 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 116 | HD-TRP (BOC) -OH | 201090-11-1 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 117 | FMOC-Tyr-OH | 92954-90-0 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 118 | H-Tyr (TBU) -oh | 18822-59-8 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 119 | FMOC-D-TYR-OH | 112883-29-1 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 120 | HD-Tyrr (ET) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 121 | H-Tyr (me) -oh.hcl | 67423-44-3 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 123 | HD-4AFH (TBUCBM) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 124 | FMOC-LYS (IPR) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 125 | H-LYS (IPR, BOC) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
Oer
Kompensaasje
Gentolex jouwe geweldige kwaliteitsprodukten, as ien produktkwaliteit wurdt ferhege troch de klant binnen it fereaske tiidrek fan foldwaande bewizen, sille wy nedige analyse jaan om de prosedueres fan kompensaasje te triggen.
Produksje
De kapasiteit fan farmaseutlike produkten berikke tonnen klasse, de kapasiteit fan gemyske produkten berikke 100tons + klasse, de mooglikheden binne goed útrist om klanten te tsjinjen.
Undersyk en ûntwikkeling
Elk jier is d'r plan opsteld troch it R & D-team om ferskate nije produkten te ûntwikkeljen, as doelstelling sil ynsteld wurde, moatte elk lid yn it team trochgean mei KPI-ferantwurdlikens en mei stimulearringsbelied.
